Revolution Medicines (RVMD) CDO Alan Sandler Sells 341 Shares

What Happened
Alan B. Sandler, Chief Development Officer at Revolution Medicines (RVMD), sold a total of 341 shares on September 16, 2026 in two open-market transactions: 5 shares at $194.96 ($975) and 336 shares at $199.30 ($66,966), for aggregate proceeds of approximately $67,941. These were sales (not purchases) and were executed pursuant to a pre-established plan to satisfy tax withholding obligations on vested restricted stock units.

Key Details

• Transaction dates and prices: 2026-09-16 — 5 shares @ $194.96; 336 shares @ $199.30.
• Total shares sold: 341; total proceeds: ~$67,941.
• Footnotes: F1 — sales made under a Rule 10b5-1 instruction adopted 6/13/2026 to satisfy tax withholding on RSU vesting. F2 — holding calculations include 209 shares acquired via the company's ESPP on 5/31/2026. F3 — holding calculations include 52,350 restricted stock units.
• Filing timeliness: Form filed 2026-09-18 for transactions on 2026-09-16 (appears timely; no late filing noted in provided details).
• Shares owned after transaction: the filing notes items included in beneficial holdings (see F2/F3); the exact post-transaction total was not provided in the summary above.

Context

• These sales were tax-withholding related under a Rule 10b5-1 plan, which is a routine administrative use of pre-set instructions and does not by itself indicate a change in the insider’s view of the company.
• For retail investors, purchases often carry more signal value than routine withholding sales; this filing appears administrative rather than strategic.